Publications by authors named "Brian Macomson"

Claim this Profile
C
Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma.
Santosh Gautam, Laura Morrison, Philippe Thompson-Leduc, Bronwyn Moore, Gordon Wong, Brian Macomson

J Manag Care Spec Pharm· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Cost of Anti-CD38 Monoclonal Antibodies in Combination With Bortezomib, Lenalidomide and Dexamethasone for the Frontline Treatment of Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma in the US.
Niodita Gupta-Werner, Vipin Khare, Brian Macomson, Rohan Medhekar

J Health Econ Outcomes Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost of Anti-CD38 Monoclonal Antibodies in Combination With Bortezomib, Lenalidomide and Dexamethasone for the Frontline Treatment of Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma in the US.
Niodita Gupta-Werner, Vipin Khare, Brian Macomson, Rohan Medhekar

J Health Econ Outcomes Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
Janice M S Lopez, Brian Macomson, Varun Ektare, Dipen Patel, Marc Botteman

Am Health Drug Benefits· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticoagulant use for the prevention of stroke in patients with atrial fibrillation: findings from a multi-payer analysis.
Kathleen Lang, Duygu Bozkaya, Aarti A Patel, Brian Macomson, Winnie Nelson

BMC Health Serv Res· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticoagulant use for prevention of stroke in a commercial population with atrial fibrillation.
Aarti A Patel, Barb Lennert, Brian Macomson, Winnie W Nelson, Gary M Owens

Am Health Drug Benefits· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis